Loading Events

« All Events

  • This event has passed.

Biofabrication & Biomanufacturing 2022

March 21, 2022 @ 8:30 am - March 22, 2022 @ 5:30 pm

SelectBIO Biofabrication and Biomanufacturing March 21-22, 2022 Boston brings together researchers from across various disciplines who are involved in the fabrication of functional, engineered tissue constructs and biomanufacturing.

This field is of great interest for generating in vitro physiological and disease models, for target identification and drug screening, and as potential organ replacements amongst other applications.

A multitude of fabrication approaches to generate tissue engineered constructs exist including photopolymerization, 3D-printing, stereolithography, multiphoton lithography as well as self-assembly approaches. While much progress has been made in generating functional tissues using both synthetic and natural materials, increasing throughput and tissue volume has been challenging. This conference will focus on advanced techniques and approaches being used for biofabrication with a focus on potentially scalable technologies that will allow higher throughput manufacturing of functional tissues.

In addition to scientific presentations, this conference features exhibits with companies showcasing their technologies and product offerings into this field.

Co-located and runs concurrently with the Innovations in Microfluidics & Single Cell Analysis 2022 Conference — Full Access to Attendees and Exhibitors for Maximal Networking.

Proof of Covid-19 Vaccination Required in Order to Participate On-Site at this Event. Participants Not Vaccinated for Covid-19 Can Participate Virtually at this Event.


March 21, 2022 @ 8:30 am
March 22, 2022 @ 5:30 pm
Event Category:

BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.




Learn more about work underway to build the biofabrication ecosystem and accelerate the science of regenerative medicine.